News

Video

Combination of Zanubrutinib + Venetoclax for Treatment-naive CLL/SLL With del(17p) and/or TP53: Preliminary Results From SEQUOIA Arm D

Author(s):

Shuo Ma, MD, PhD

Preliminary results for treatment with zanubrutinib + venetoclax in patients with high-risk TN CLL/SLL with del(17p) and/or TP53 mutation showed Promising efficacy in a high-risk population with deep and durable responses according to data from arm D of the phase 3 SEQUOIA trial (NCT03336333).

Related Videos
Phase 3 AMPLIFY Trial
Guillermo Garcia-Manero, MD
Alvaro Alencar, MD
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, highlight key data in CML and ALL presented at the 2024 ASH Annual Meeting.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, detail factors for selecting a TKI in later lines of therapy in chronic myeloid leukemia.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss data for ponatinib plus chemotherapy in Ph-positive ALL.
Related Content
Diffuse Large B-cell Lymphoma | Image Credit: © LASZLO – stock.adobe.com
January 28th 2025

Rapcabtagene Autoleucel May Be Safe and Efficacious in R/R DLBCL

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

The OncFive: OncLive's Top Oncology Articles for the Week of 1/19
January 25th 2025

The OncFive: Top Oncology Articles for the Week of 1/19

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Acute Myeloid Leukemia | stock.adobe.com
January 23rd 2025

Maintenance Galinpepimut-S Appears Effective and Safe in AML in Second CR

Chronic Lymphocytic Leukemia |Image Credit: © LASZLO – stock.adobe.com
January 22nd 2025

Ibrutinib/Venetoclax Combo Demonstrates Sustained TEAE-Free PFS in First-Line CLL